Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

Efineptakin alfa

Source date not recordedAnalyse record ↗

Clinical-stage long-acting IL-7 fusion protein being advanced for thymic function and immune resilience in immunologically vulnerable populations.

Modality
long-acting recombinant human IL-7 fusion protein
Availability (US)
Clinical-stage; thymic-function Phase 2 studies planned
Biomarkers
CD4 and CD8 T-cell counts; Ki-67; BCL-2; T-cell receptor diversity; thymic output
Hallmark targeted
altered intercellular communication, immune aging
Kind
investigational biologic
Other papers
Kim et al., Cell Reports Medicine 2022; PMCID PMC9772483